Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05217706
Recruitment Status : Recruiting
First Posted : February 1, 2022
Last Update Posted : March 21, 2022
Sponsor:
Collaborator:
University of California, San Diego
Information provided by (Responsible Party):
Tanya Vayngortin, Rady Children's Hospital, San Diego

Tracking Information
First Submitted Date  ICMJE December 15, 2021
First Posted Date  ICMJE February 1, 2022
Last Update Posted Date March 21, 2022
Actual Study Start Date  ICMJE March 1, 2022
Estimated Primary Completion Date January 1, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 19, 2022)
Change in Beck Depression Inventory Depression sub-scale Score [ Time Frame: 1 hour, 3 hours, 1 day, 3 days, 7 days after treatment ]
Beck depression inventory score, 0-20 (higher score associated with worse depression)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 19, 2022)
  • Change in Beck Depression Inventory anxiety sub-scale score [ Time Frame: 1 hour, 3 hours, 1 day, 3 days, 7 days after treatment ]
    Depression sub-score, 0-20 (higher score associated with worse anxiety)
  • Change in Beck Depression Inventory self-concept sub-scale score [ Time Frame: 1 hour, 3 hours, 1 day, 3 days, 7 days after treatment ]
    Depression sub-score, 0-20 (higher score associated with worse self-concept)
  • Change in Suicidal Ideation Questionnaire score [ Time Frame: 1 hour, 3 hours, 1 day, 3 days, 7 days after treatment ]
    Suicidal Ideation score, 0-120 (higher score associated with higher suicide risk)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department
Official Title  ICMJE Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department: A Randomized Placebo-Controlled Trial
Brief Summary The goal of this study is to test whether a single low-dose of IV ketamine given in the emergency department to adolescents with treatment-resistant depression and suicidal ideation can reduce depression symptoms and suicidal thoughts compared to placebo. Participants will complete depression scales at baseline, and 1 hour, 3 hours, 1 day, 3 days, and 7 days after receiving the treatment.
Detailed Description

This study will be a double-blinded, randomized, placebo-controlled trial. Study investigators and trained research assistants (RAs) will identify eligible participants from the electronic ED tracking board based on inclusion criteria, and will confirm eligibility with the treating physician. After a patient has been evaluated by nursing, physician, and social worker and has been determined to require inpatient psychiatric admission, the patient and parent/guardian will be approached for the study. A parent/guardian must be available in person or by phone to provide consent, and the adolescent will provide assent. The RA or investigator will collect demographic data and psychiatric history from the electronic medical record to verify eligibility criteria, and will confirm with the treating physician that the patient can participate in the study. The RA or investigator will provide the patient self-administered scales, including the Suicidal Ideation Questionnaire and the Beck Depression, Anxiety, and Self-Concept Scales.

After the patient has assented and parent/guardian has consented to participation in the study, a study physician will initiate the electronic study order set. The Investigational Drug Service Pharmacy at RCHSD will dispense either ketamine 0.2 mg/kg (minimum 10 mg, maximum 20 mg) or normal saline in the same volume in identically-appearing syringe, based upon a pre-determined randomization scheme kept only in the pharmacy. The study will be blinded to ordering and treating providers, as well as the RA and nurse. The investigators will use an online randomization tool, and randomization will be even between the two groups. S An ED nurse will place an IV catheter if the patient does not already have one, and will record heart rate, blood pressure, respiratory rate, oxygen saturation immediately before the infusion and 5 minutes after. The medication will be given over 2 minutes by a nurse, who will remain in the room for 5 minutes after infusion. The patient will remain on pulse oximeter for 30 minutes. The RA or study investigator will administer a post-infusion survey to document any adverse effects and will record pre- and post-infusion vital signs 5 minutes after infusion. The IV catheter will then be removed unless required for another clinical indication as determined by the treating physician. After the 30 minute monitoring period, the patient will resume standard ED care and can be transferred to the psychiatric ED or CAPS whenever the bed is available. The RA or investigator will administer follow up depression and SI scales after 1 hour, 3 hours, 1 day, 3 days, and 7 days either in the psychiatric ED or CAPS, or by telephone if the patient has been discharged.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
double-blinded randomized controlled trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The enroller, treating provider, and patient are masked. Only the pharmacist will be un-masked, as they are preparing the medication or placebo.
Primary Purpose: Treatment
Condition  ICMJE
  • Depression
  • Suicidal Ideation
Intervention  ICMJE
  • Drug: Ketamine
    The treatment group will receive Ketamine 0.2mg/kg IV once
  • Drug: normal Saline
    The placebo group will receive normal saline IV in a matched syringe
Study Arms  ICMJE
  • Experimental: Treatment
    This group will be given ketamine 0.2mg/kg
    Intervention: Drug: Ketamine
  • Placebo Comparator: Placebo
    This group will be given normal saline in matched syringe
    Intervention: Drug: normal Saline
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 19, 2022)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 1, 2023
Estimated Primary Completion Date January 1, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Determined, based upon medical and social work evaluation, to require inpatient psychiatric admission without further need for medical diagnostic evaluation and treatment.
  • Treatment-resistant depression (defined as failure of response to trials of at least 2 antidepressant courses, each of at least 4 weeks' duration)
  • Parent/guardian available for consent (in person or by phone)

Exclusion Criteria:

  • Any of the following co-existing diagnoses: primary psychotic disorder (schizophrenia, schizoaffective) autism spectrum disorder, developmental delay/intellectual disability, substance abuse disorder within the last 6 months
  • Aggressive behavior, homicidal ideation
  • Altered mental status
  • Pregnancy or breastfeeding,
  • Currently receiving (or receipt within last 24 hours) medication acting on NMDA receptor system (lamotrigine, dextromethorphan, methadone, clarithromycin, amantadine)
  • Incomplete medical evaluation or stabilization
  • Contraindications to or anaphylaxis or prior adverse reaction to Ketamine
  • No caregiver available
  • In custody of a law enforcement agency
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Tatyana Vayngortin, MD 8589668036 tvayngortin@rchsd.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05217706
Other Study ID Numbers  ICMJE 800170
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: Study data will be published in the future
Current Responsible Party Tanya Vayngortin, Rady Children's Hospital, San Diego
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Rady Children's Hospital, San Diego
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE University of California, San Diego
Investigators  ICMJE Not Provided
PRS Account Rady Children's Hospital, San Diego
Verification Date March 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP